NEXAVAR
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.
Natco Pharma's partner MylanInc gets USFDA nod for cancer drug
The company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA).
Natco Pharma's US partner Mylan files application with USFDA
Natco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly for treatment of liver and kidney cancers.
Bayer challenges IPAB’s compulsory licence order to Natco Pharma on cancer drug Nexavar
“We introduce the product after years of research and investment, while companies like Natco merely copy and manufacture the product,” said Ravi Kadam.
IPAB allows Natco Pharma to sell Nexavar; stock gains
'Company will continue to market and sell the drug post verdict. It sold Rs 14 crore worth of Nexavar drug in the past 9 months.'
Bayer says it will defend its intellectual property rights on cancer drug
Bayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to stay the compulsory license granted to Natco.
Intellectual Property Appellate Board postpones Bayer's compulsory licence appeal
IPAB has postponed German company Bayer AG's appeal against the grant of a compulsory licence of its patented drug Nexavar to Natco Pharma to September 3
US accuses India of WTO rules violation over Nexavar: Report
The government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.
US threatens to take India to WTO over Nexavar Generic
The US has threatened to drag India to the WTO for issuing the firstever compulsory licence to a domestic company to manufacture generic version of Bayer's cancer drug Nexavar.
Bayer demands withdrawal of Natco Pharma's compulsory licence
In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's price.
Cipla breached patent rights by slashing cancer drug price: Bayer Pharma
Bayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer spokesperson said.
Bayer challenges Nexavar generic licence order
Bayer has filed an appeal against a patents order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German firm's cancer drug 'Nexavar' in India.
Natco Pharma bags licence to sell Nexavar drug; stock up
Shares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for the generic version of Nexavar.
Natco may seek compulsory licence for Bayer's cancer drug
Natco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic drugmakers to make & sell patented drugs cheaply if medicine is unaffordable.
Bayer drags Cipla to court over patent
German drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based company from selling its generic version of controversial cancer medicine Nexavar (chemical name Sorafenib Tosylate).
SC rejects Bayer’s plea to stay Cipla’s cancer clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Bayer’s patented cancer medicine Nexavar while admitting the case.
No interim stay on Cipla’s Nexavar clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Bayer’s patented cancer medicine Nexavar while admitting the case.
Bayer’s bid to stay Cipla cancer drug foiled, next hearing on Oct 6
Germany's largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European company’s copycat of cancer treating drug, Nexavar, in India.
Cipla's clone of Bayer cancer drug gets nod
This case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
Load More
